Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Enliven Therapeutics, Inc. | Director | Stock Option (right to buy) | 23.4K | Feb 13, 2024 | Direct | ||
MoonLake Immunotherapeutics | Director | Option to Buy | 7.69K | Jun 6, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
MLTX | MoonLake Immunotherapeutics | Jun 6, 2024 | 1 | $0 | 4 | Jun 7, 2024 | Director |
ELVN | Enliven Therapeutics, Inc. | Feb 13, 2024 | 1 | $0 | 4/A | Feb 20, 2024 | Director |
ELVN | Enliven Therapeutics, Inc. | Feb 13, 2024 | 1 | $0 | 4 | Feb 15, 2024 | Director |
MLTX | MoonLake Immunotherapeutics | Jun 8, 2023 | 1 | $0 | 4 | Jun 12, 2023 | Director |
ELVN | Enliven Therapeutics, Inc. | Feb 23, 2023 | 1 | $0 | 4 | Apr 6, 2023 | Director |
ELVN | Enliven Therapeutics, Inc. | Feb 23, 2023 | 0 | $0 | 3 | Feb 27, 2023 | Director |
MLTX | MoonLake Immunotherapeutics | Apr 6, 2022 | 1 | $0 | 4 | May 5, 2022 | Director |
MLTX | MoonLake Immunotherapeutics | Apr 5, 2022 | 0 | $0 | 3 | Apr 15, 2022 | Director |